NMN vs. NR: The Complete European Buyer's Guide to NAD+ Supplements (2026)

Your NAD+ levels are roughly half what they were at 20. By the time you hit 60, they may be down by 50% or more. That single biochemical fact sits at the center of most serious longevity research today — and it's what turned NAD+ precursor supplements from a niche biohacker obsession into a mainstream conversation driven by researchers like David Sinclair at Harvard and popularized by figures like Andrew Huberman.

Two molecules dominate that conversation: nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). Both are precursors that your body converts into NAD+. Both are backed by a growing body of human clinical trials. But they are not the same thing, the evidence base is not equivalent, and — critically for anyone buying in Europe — their regulatory status differs significantly.

This guide cuts through the noise. You'll get the actual science, the actual legal picture as of 2026, and a practical comparison of brands available to buyers in the EU, UK, Switzerland, and Norway.

The NAD+ Decline Problem: Why This Matters

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell in your body. It drives over 500 enzymatic reactions, powers mitochondrial energy production, activates sirtuins (the enzymes most associated with longevity signaling), and enables DNA repair through PARP enzymes. Without adequate NAD+, these systems slow down.

The problem is that NAD+ biosynthesis declines with age. Studies measuring NAD+ levels in human skin, blood, liver, muscle, and brain consistently show this decline — the drop is measurable by your 30s and becomes significant by your 40s. An enzyme called CD38, which consumes NAD+ and increases in abundance with age and low-grade inflammation, contributes substantially to this depletion.

This is the biological rationale behind supplementing with NAD+ precursors. You can't take NAD+ directly in oral form with meaningful results — it degrades before absorption. Instead, you provide the building blocks your cells use to synthesize it.

NMN and NR are those building blocks. They sit at different points in the same biosynthesis pathway, which is exactly why the choice between them matters.

NMN vs. NR: How They Actually Work

The Biosynthesis Pathway

Understanding the difference requires a quick look at the salvage pathway — the main route your body uses to recycle and generate NAD+.

The pathway looks like this:

Tryptophan (de novo) ──────────────────────────────────┐
Nicotinic Acid (Preiss-Handler) ────────────────────────┤
                                                         ▼
Nicotinamide (NAM) → NMN → NAD+
         ↑                  ↑
         NR ────────────────┘

NR (nicotinamide riboside) is converted to NMN by enzymes called NRKs (nicotinamide riboside kinases). NMN is then converted to NAD+ by NMNAT enzymes. So NR has one additional enzymatic step compared to NMN.

NMN is the more direct precursor. NR feeds into the same pathway but sits one step earlier in the conversion sequence.

Bioavailability: The Absorption Debate

This is where things get genuinely contested.

Early research suggested that NMN could not enter cells directly and needed to first be converted to NR, then re-phosphorylated back to NMN, and finally converted to NAD+. A 2019 paper by Grozio et al. identified a specific transporter, Slc12a8, that appeared to transport NMN directly into intestinal cells in mice — suggesting direct uptake was possible.

In humans, the picture is clearer than many supplement brands suggest. Oral NMN is rapidly absorbed and metabolized. Multiple clinical trials, including Fukamizu et al. (2022) published in Frontiers in Nutrition, confirm that oral NMN administration safely and efficiently increases blood NAD+ levels — the compound does not need to first convert to NR to be effective.

For NR, the absorption mechanism is well-established: it enters cells via NRK-mediated phosphorylation. Both compounds effectively raise blood NAD+ in humans, but the magnitude and tissue distribution may differ. The clinical evidence reviewed below shows NMN tends to produce larger and more consistent NAD+ elevations at comparable doses.

Molecular Weight and Dosing

What Human Clinical Trials Actually Show

This is the section that separates a legitimate guide from supplement marketing copy. Here is what the published, peer-reviewed evidence says — not animal studies, not in-vitro data.

NMN Clinical Evidence

Yoshino et al. (2021) — Science
The landmark NMN human trial. Washington University researchers conducted a 10-week, randomized, placebo-controlled, double-blind trial in 25 postmenopausal women who were overweight or obese with prediabetes. The NMN group (250 mg/day) showed significantly improved muscle insulin sensitivity, increased skeletal muscle insulin signaling (AKT and mTOR phosphorylation), and up-regulation of genes related to muscle remodeling. The study was published in Science (DOI: 10.1126/science.abe9985). It remains one of the most cited human NMN trials.

Yi et al. (2022) — GeroScience
A multicenter, randomized, double-blind, placebo-controlled trial in 80 healthy middle-aged adults. Participants took 300 mg, 600 mg, or 900 mg NMN daily for 60 days. All NMN groups showed statistically significant increases in blood NAD+ versus placebo (p ≤ 0.001). Physical performance (six-minute walk test) improved significantly across all NMN groups. Notably, the blood biological age stayed stable in NMN-treated groups but increased in the placebo group by day 60 (DOI: 10.1007/s11357-022-00705-1). The 600 mg dose produced the strongest results.

Irie et al. (2020) — Endocrine Journal
A single-arm, dose-escalation trial at Keio University, Japan. Ten healthy men received single oral doses of 100, 250, and 500 mg NMN. No significant adverse clinical symptoms, changes in vital signs, or concerning laboratory abnormalities were observed. NMN metabolites increased dose-dependently in plasma, confirming absorption and metabolism (DOI: 10.1507/endocrj.EJ19-0313).

Yamaguchi et al. / Igarashi group (2024) — Endocrine Journal
An 8-week open-label trial in 11 healthy middle-aged Japanese men taking 250 mg NMN daily (two 125 mg capsules). NAD+ levels in peripheral blood mononuclear cells increased throughout the supplementation period. In a subset of participants with insulin oversecretion, NMN modestly attenuated postprandial hyperinsulinemia (DOI: 10.1507/endocrj.ej23-0431).

Liao et al. (2021) — Journal of the International Society of Sports Nutrition
A 6-week, randomized, double-blind, placebo-controlled, four-arm trial in 48 recreationally trained runners. Doses of 300 mg, 600 mg, and 1200 mg NMN were tested. The medium (600 mg) and high (1200 mg) dose groups showed significantly greater increases in oxygen uptake and ventilatory threshold compared to placebo, suggesting improved aerobic capacity through enhanced skeletal muscle oxygen utilization (DOI: 10.1186/s12970-021-00442-4).

Summary of NMN findings: Consistent NAD+ elevation across doses of 250–900 mg/day. Strongest functional effects at 600 mg/day. Well tolerated with no serious adverse events reported across trials. Metabolic and physical performance benefits shown in multiple populations.

NR Clinical Evidence

Martens et al. (2018) — Nature Communications
A pivotal 2 × 6-week randomized, double-blind, placebo-controlled, crossover trial in 24 healthy middle-aged and older adults. Chronic NR supplementation (500 mg/day) was well tolerated and significantly elevated blood NAD+ metabolism, including increases in NAD+ and nicotinamide-related metabolites. This established the foundational human safety and efficacy profile for NR (DOI: 10.1038/s41467-018-03421-7).

Elhassan et al. (2019) — Cell Reports
Compared NR supplementation (1000 mg/day for 6 weeks) to placebo in 12 healthy older men. NR increased skeletal muscle NAD+ by over 50% versus no change with placebo. The study also noted that NR supplementation markedly reduced levels of circular mitochondrial DNA, a marker of mitochondrial stress, in muscle tissue.

Norheim et al. (2024) — Nature Aging
A randomized, double-blind, placebo-controlled trial in 40 patients with stable COPD treated with NR for 6 weeks. The primary outcome — sputum interleukin-8 — decreased by an estimated 52.6% in the NR group versus placebo (p = 0.030). NAD+ levels in whole blood more than doubled. The effect persisted at a 12-week follow-up (DOI: 10.1038/s43587-024-00758-1).

McDermott et al. / NICE trial (2024) — Nature Communications
In 90 adults with peripheral artery disease, 6 months of NR supplementation significantly improved 6-minute walk distance (+17.6 meters versus placebo). Among participants who took at least 75% of study pills, improvement reached 31.0 meters (DOI: 10.1038/s41467-024-49092-5).

Wu et al. (2025) — eClinicalMedicine
In 58 adults with long-COVID, NR (2000 mg/day) increased NAD+ levels 2.6- to 3.1-fold within 5–10 weeks. No significant between-group differences were observed in cognitive outcomes versus placebo. Exploratory within-group analyses suggested improvements in executive functioning, fatigue, and sleep quality after 10 weeks of NR (DOI: 10.1016/j.eclinm.2025.103633).

Summary of NR findings: Strong and consistent NAD+ elevation, robust safety record across a larger body of trials (NR has been studied since 2017). Strongest evidence in cardiovascular and inflammatory contexts. Cognitive benefit evidence is mixed.

Head-to-Head Comparison: What the Evidence Says

NR has a longer human evidence track record simply because it entered commercial and clinical research earlier — ChromaDex's NIAGEN ingredient has been the subject of systematic research since 2017. NMN trials are accelerating quickly and the Yi et al. (2022) dose-response data is among the most rigorous in the NAD+ precursor space.

NMN Legal Status in Europe: What You Need to Know in 2026

This section matters more for European buyers than almost anything else. The regulatory situation is genuinely complex, and several vendors are actively misrepresenting it.

The EU Novel Food Framework

Under EU Regulation 2015/2283, any food or food ingredient without a history of significant consumption in the European Union before May 15, 1997 is classified as a "novel food." Novel foods require pre-market authorization — a full safety assessment by the European Food Safety Authority (EFSA) — before they can be legally marketed in EU member states.

NMN falls squarely into this category. It has no documented history of significant consumption in Europe before the 1997 cutoff. This is not a grey area.

What this means in practice: As of March 2026, no NMN product has received Novel Food authorization in the EU. Selling NMN supplements to EU consumers without authorization is technically non-compliant. EU food safety authorities can and do act on this — the EU's RASFF (Rapid Alert System for Food and Feed) has flagged NMN supplements as unauthorized (RASFF notification, January 2024).

Where Applications Stand (March 2026)

Six Novel Food applications for NMN have been submitted to EFSA as of December 2025, according to CIRS Group regulatory tracking:

Uthever — the branded NMN ingredient used by several supplement companies — completed the EU Novel Food public consultation phase in February 2025 and is currently in EFSA's risk assessment stage, according to Uthever's own regulatory communications. This makes it the furthest advanced NMN application in the EU pipeline. Authorization, if granted, typically follows 6–12 months after risk assessment completion — meaning the earliest plausible EU authorization date is late 2025 to mid-2026.

The EFSA process for novel foods takes 18–24 months from submission to European Commission approval. The overall approval rate remains below 30%, per EFSA's own published statistics.

UK Post-Brexit Position

The UK maintains its own novel food regime under the Food Standards Agency (FSA) following Brexit. The framework mirrors the EU's 1997 consumption history cutoff. NMN has not received Novel Food authorization from the FSA as of March 2026. NMN is legal for personal purchase in the UK but cannot be legally marketed as a food supplement until authorized. The FSA's review process runs independently of EFSA.

Switzerland and Norway

Both countries are not EU members but participate in or closely align with EU food safety frameworks:

• Switzerland: The Swiss Federal Food Safety and Veterinary Office (FSVO) applies similar novel food principles. NMN is not authorized as a food supplement ingredient in Switzerland.
• Norway: As an EEA (European Economic Area) member, Norway applies EU Novel Food Regulation 2015/2283 directly. NMN is not authorized in Norway.

What This Means for Buyers

The practical situation in 2026: NMN supplements are widely available online in Europe, and personal import and use is not prohibited. However, the grey market nature of the current EU supply carries real risks:

1. No EFSA safety review completed — quality standards and maximum dosages have not been formally assessed for European consumers
2. Variable enforcement — some national authorities (notably Italy and certain Nordic countries) have been more active in removing unauthorized novel foods from shelves
3. No EU-compliant health claims — any brand making health claims about NMN on its EU marketing is operating outside authorized claim territory

NR's regulatory position is markedly different. NR has Novel Food authorization in the EU under ChromaDex's NIAGEN ingredient (authorized 2021, renewed for continued use). It can be legally marketed in EU food supplements. This is a material advantage for buyers who want a product with full regulatory backing.

What to Look for in a Brand: European Buyer Standards

Given the regulatory environment, due diligence when selecting a brand is not optional. Here is what to check.

Purity and Third-Party Testing

The minimum standard is a Certificate of Analysis (CoA) from an independent, accredited laboratory confirming:

• NMN purity ≥ 99% (HPLC method, ideally USP/NF, EP, or JP standard)
• Heavy metals testing (lead, arsenic, cadmium, mercury)
• Microbial testing (total aerobic count, yeast/mold, E. coli, Salmonella)
• Absence of residual solvents

Batch-specific CoAs are the gold standard. Generic "we test our products" statements are not. Look for a CoA with a lot number that matches the product you're buying.

NMN Ingredient Source

For NMN, the dominant commercially pure ingredients come from enzymatic synthesis processes. The two most tracked ingredients in the EU compliance pipeline are:

• Uthever NMN — produced by Effepharm/NovaBay, furthest advanced in EFSA review. Used by brands such as For Youth, MoleQlar, and others.
• SyncoZymes NMN — Chinese manufacturer with a submitted EFSA dossier; also the basis for the FDA-authorized US NDI.

For NR, NIAGEN by ChromaDex is the only NR ingredient with full Novel Food authorization in the EU. If a brand uses a generic NR ingredient without disclosing the supplier, that is a red flag for both regulatory compliance and quality.

Manufacturing Standards

• GMP-certified manufacturing facility (EU GMP, US FDA GMP, or equivalent)
• No proprietary blends that obscure actual NMN/NR content
• Clearly stated dose per capsule (not per serving if a serving is multiple capsules)

Label Compliance

EU food supplement labels must:

• Not make unauthorized health claims (no claims about treating, preventing, or curing diseases)
• Include a recommended daily intake that does not imply medicinal use
• List all ingredients, including excipients (fillers, capsule material)

Brands selling into the EU market and making claims like "clinically proven to reverse aging" are operating outside EU food law regardless of NMN's authorization status.

European Brand Comparison Table

The following brands are currently available to buyers in the EU, UK, Switzerland, and/or Norway. Prices are approximate as of Q1 2026.

Who Should Choose NMN, Who Should Choose NR, and at What Dose

Choose NMN if:

• You are primarily focused on metabolic health and physical performance
• You are comfortable with the current EU regulatory grey area and want to monitor EFSA authorization progress
• You want access to the most recent and rapidly growing clinical evidence base
• You are 40+ and looking for a higher-dose protocol (600–900 mg/day is where the strongest performance data sits)
• You have access to a reputable brand using Uthever or SyncoZymes NMN with third-party CoAs

Starting dose: 250–500 mg/day in the morning. Evidence suggests 600 mg/day for stronger effects in physically active individuals (Liao et al., 2021; Yi et al., 2022).

Choose NR if:

• EU regulatory compliance matters to you — NR with NIAGEN is authorized, NMN is not
• You have a cardiovascular health focus (the NICE trial walking distance data is compelling)
• You have chronic inflammatory conditions or lung disease (Norheim et al., 2024 COPD data)
• You want the longest-established human safety record for an NAD+ precursor
• You are building or evaluating a supplement stack for a clinical or institutional context where regulatory status matters

Starting dose: 300 mg/day (Tru Niagen standard dose). Evidence for cardiovascular benefit used 1000 mg/day in some trials. Dosing above 1000 mg/day does not appear to produce proportionally greater NAD+ elevation.

Decision Table

FAQ

Is NMN legal to buy in Europe?

In most EU countries, you can legally purchase NMN for personal use. It is widely available online. However, NMN does not have EU Novel Food authorization as of March 2026, which means it cannot be legally marketed as a food supplement ingredient within the EU. The enforcement of this distinction varies by country. Italy and Nordic countries have historically been more active in removing unauthorized novel foods from commercial shelves. If regulatory compliance is important to you, NR with NIAGEN is the better choice.

Is NR a weaker version of NMN?

No. NR requires one additional enzymatic conversion step to reach NAD+, but this does not make it "weaker" in clinical use. Both compounds effectively raise blood NAD+ in humans. NR's human evidence base is actually larger because it has been in formal clinical trials longer. Describing NR as inferior to NMN is supplement marketing, not science.

Can I take NMN and NR together?

Yes. They act on the same pathway, so you are essentially providing precursor redundancy. Some formulations (like Perpetua.Life AEON) combine both. There is no published evidence of interaction toxicity. That said, there is also no strong published evidence that the combination is superior to an optimized dose of either alone. Stacking both is not irrational but is more expensive.

When will NMN be authorized in the EU?

Based on current EFSA pipeline status as of March 2026, the Uthever application is furthest advanced — it completed public consultation in February 2025 and is now in the risk assessment phase. If assessment proceeds without complications, European Commission authorization could come within 6–18 months of risk assessment completion. Realistically, the earliest plausible EU authorization date is late 2026 to mid-2027. Track the EFSA Novel Food register for updates.

What dose of NMN is actually supported by clinical evidence?

The dose-response data from Yi et al. (2022) is the clearest reference: 300 mg, 600 mg, and 900 mg all raised NAD+ significantly versus placebo, with the 600 mg and 900 mg groups showing the strongest effects on both NAD+ levels and physical performance. The Yoshino et al. (2021) Science trial used 250 mg/day in a specific population (postmenopausal women with prediabetes). For general longevity use in otherwise healthy adults, 500–600 mg/day appears to be the sweet spot between cost and clinical effect. Starting at 250 mg/day and assessing tolerance for 4–6 weeks before increasing is a reasonable approach.

Does the form of delivery (capsule vs. sublingual vs. liposomal) matter?

Standard capsules are effective — multiple randomized controlled trials demonstrating NAD+ elevation used standard oral capsules. Sublingual and liposomal forms may improve bioavailability in theory, but there are no published comparative human trials proving they deliver meaningfully superior NAD+ increases at equivalent doses. These formats command a significant price premium. The evidence base was built primarily on standard oral capsule forms, and that is what you should default to unless there is a specific reason otherwise.

I've heard NMN can be degraded in the gut. Should I be worried?

Some early research raised questions about gut degradation of NMN before absorption. Subsequent human pharmacokinetic studies, including Fukamizu et al. (2022), demonstrated that oral NMN does successfully raise blood NAD+ levels — the compound or its direct metabolites reach tissues and drive NAD+ synthesis. Degradation to nicotinamide before absorption may be part of the mechanism, but the endpoint that matters — elevated blood and tissue NAD+ — has been repeatedly demonstrated in human trials.

The Bottom Line

The NMN vs. NR decision for European buyers is not just a biochemistry question — it's a regulatory one.

On the science: Both compounds raise NAD+ in humans. NMN has a slightly more direct conversion pathway and rapidly accumulating evidence for metabolic and physical performance benefits. NR has a longer-established human safety and efficacy record, with particularly strong cardiovascular data.

On regulation: NR with NIAGEN is EU-authorized. NMN is not. This is not a minor footnote — it's the determinant factor for buyers who want a fully compliant, legally marketed supplement.

The pragmatic position in 2026: If you want regulatory peace of mind, choose Tru Niagen (NIAGEN NR, 300–1000 mg/day). If you're comfortable buying in the grey market while EFSA processes NMN applications, choose a brand using Uthever NMN with third-party batch CoAs at 500–600 mg/day. In either case, verify the CoA, don't pay for delivery formats that have no clinical backing, and track EFSA's novel food register — EU NMN authorization may arrive within 12–18 months.